文献速递临床试验与 GCP

两种阿育吠陀剂型治疗过敏性鼻炎:开放标签随机对照试验研究方案

Efficacy and safety of two Ayurvedic dosage forms for allergic rhinitis: Study protocol for an open-label randomized controlled trial.
PubMed 文献 · Trials · 2020-01-07

本研究为三臂、开放标签、非劣效性随机对照试验,纳入过敏性鼻炎患者,比较含12种成分的Tamalakyadi汤剂及其冻干制剂与抗组胺药氯雷他定的疗效与安全性。主要终点为28天总鼻症状评分(TNSS),随访至第2个月。

要点

  • 比较阿育吠陀汤剂TMD12、其冻干制剂与氯雷他定治疗过敏性鼻炎。
  • 主要疗效终点为总鼻症状评分(TNSS),用药28天并随访2个月。
  • 试验注册号ISRCTN18149439,注册日期2019年5月6日。

核心结论

  • 该试验旨在为TMD12及其冻干制剂治疗过敏性鼻炎提供循证科学数据。

研究设计与样本

  • 三臂、开放标签、非劣效性随机对照临床试验,纳入过敏性鼻炎患者。
  • 患者经1周导入期后随机分入三组,口服药物28天。

关键数值与推荐

  • 主要疗效终点为总鼻症状评分(TNSS),在访视1前、28天结束时及随访第1、2个月末记录并比较。
  • 次要终点包括日间鼻症状评分、夜间鼻症状评分、非鼻症状评分及健康相关生活质量问卷。
  • 试验注册号ISRCTN18149439(2019年5月6日)。

局限性

  • 研究方案未报告样本量、效应阈值或统计假设等具体数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Allergic rhinitis (AR) is an immune response of the nasal mucosa to airborne allergens and involves nasal congestion, watery nasal discharge, itching of the nose, and sneezing. The symptoms of allergic rhinitis may significantly affect a patient's quality of life and can be associated with conditions such as fatigue, headache, cognitive impairment, and sleep disturbances. Various complementary and alternative medicine treatments have been used for this condition in clinical practice. The Ayurveda system of medicine is the most common complementary medicine system practiced in Sri Lanka. The aim of this study is to examine the efficacy and safety of a decoction used in traditional Ayurveda for allergic rhinitis and its ready- to-use freeze dried formulation in comparison to an antihistamine over a period of 4 weeks on relief of symptoms in allergic rhinitis. STUDY DESIGN: This is a three-arm, open-label, non-inferiority, randomized controlled clinical trial enrolling patients with AR. Tamalakyadi decoction containing 12 ingredients (TMD12), used in traditional Ayurveda and its freeze-dried formulation are the test products. The efficacy and safety of the two Ayurvedic dosage forms will be tested against the antihistamine loratadine. Patients with symptoms of AR will be allocated randomly into the three arms after a 1-week run-in period and the medications will be given orally for 28 days. Total Nasal symptom Score (TNSS) of the patients will be used as the primary efficacy endpoint. TNSS will be recorded and compared between the three arms prior to visit 1, at the end of 28 days, and end of the first and second months of follow-up. Symptom scores of daytime nasal symptoms, night time nasal symptoms, non-nasal symptoms and health-related quality of life questionnaire are used as secondary end points. DISCUSSION: This clinical trial will be able to provide evidence-based scientific data on Ayurvedic dosage form, TMD12, and the freeze-dried formulation in the treatment of allergic rhinitis. This trial is expected to develop capacity to scientifically evaluate various Ayurvedic treatments that are claimed to have efficacy in treatment of various disease conditions. TRIAL REGISTRATION: ISRCTN18149439 (6 May 2019).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Dahanayake JM, Perera PK, Galappaththy P, et al. Efficacy and safety of two Ayurvedic dosage forms for allergic rhinitis: Study protocol for an open-label randomized controlled trial. Trials. 2020. PMID: 31910896. doi:10.1186/s13063-019-4004-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。